Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Isophthalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.62 |
| ▸ | CA1 | P00915 | 1/20 | 0.62 |
| ▸ | CA2 | P00918 | 1/20 | 0.62 |
| ▸ | CA6 | P23280 | 1/20 | 0.62 |
| ▸ | CA9 | Q16790 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.58 |
| ▸ | KMO | O15229 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | DAO | P14920 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.57 |
| ▸ | UNG | P13051 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.54 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isophthalic Acid SCHEMBL28834662 | 0.95 | CA12 (0.62) | CA12CA1CA2CA6CA9 | |
| Isophthalic Acid SCHEMBL30529662 | 0.92 | CA12 (0.65) | CA12CA1CA2CA6CA9 | |
| Isophthalic Acid SCHEMBL28756611 | 0.92 | CA12 (0.71) | CA12CA1CA2CA6CA9 | |
| Isophthalic Acid SCHEMBL22462 | 0.92 | CA12 (0.71) | CA12CA1CA2CA6CA9 | |
| Isophthalic Acid SCHEMBL28462260 | 0.92 | CA12 (0.71) | CA12CA1CA2CA6CA9 | |
| Isophthalic Acid SCHEMBL147366 | 0.92 | CA12 (0.71) | CA12CA1CA2CA6CA9 | |
| Isophthalic Acid SCHEMBL2512374 | 0.92 | CA12 (0.71) | CA12CA1CA2CA6CA9 | |
| Isophthalic Acid SCHEMBL20500514 | 0.92 | CA12 (0.71) | CA12CA1CA2CA6CA9 | |
| SCHEMBL4957430 | 0.90 | HSD17B10 (0.65) | CA12CA1CA2CA6CA9 | |
| SCHEMBL29902348 | 0.90 | CA12 (0.58) | CA12CA1CA2CA6CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 904 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3925601-B1 | GASTRO-RESISTANT FORMULATION CONTAINING POSACONAZOLE AND A POLYMERIC PRECIPITATION INHIBITOR | TIEFENBACHER ALFRED E GMBH & CO KG (DE) | 2024-07-17 | — | — | EP | claimed |
| US-20240207264-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING INHIBITORS OF THE ANDROGEN RECEPTOR AND USES THEREOF | ESSA PHARMA INC. (CA) | 2024-06-27 | — | — | US | claimed |
| WO-2024119044-A2 | ADRULIPASE COMPOSITIONS | First Wave BioPharma, Inc. (US) | 2024-06-06 | — | — | WO | claimed |
| EP-4322933-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING INHIBITORS OF THE ANDROGEN RECEPTOR AND USES THEREOF | ESSA PHARMA INC. (CA) | 2024-02-21 | — | — | EP | claimed |
| WO-2024035618-A1 | PROCESSES FOR PREPARING OXAZOLIDINONE COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2024-02-15 | — | — | WO | claimed |
| US-20240009135-A1 | DENSIFIED CO-PRECIPITATED MATERIALS ISOLATED BY THIN FILM EVAPORATION | MERCK SHARP & DOHME LLC (US) | 2024-01-11 | — | — | US | claimed |
| EP-4084778-B1 | AMORPHOUS KINASE INHIBITOR FORMULATIONS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS LLC (US) | 2023-11-01 | — | — | EP | claimed |
| US-20230285352-A1 | Dihydromyricetin Hot Melt Extrusion Formulations and Methods for Forming Them | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2023-09-14 | — | — | US | claimed |
| EP-4214183-A1 | PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS COMPRISING INHIBITORS OF THE ANDROGEN RECEPTOR AND USES THEREOF | Essa Pharma, Inc. (CA) | 2023-07-26 | — | — | EP | claimed |
| CN-116437947-A | Non-pig formulations and methods thereof | 第一浪潮生物制药有限公司 | 2023-07-14 | — | — | CN | claimed |
| WO-2002011710-A2 | PHARMACEUTICAL COMPOSITIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | PFIZER PRODUCTS INC. (US) | 2002-02-14 | — | — | WO | claimed |
| US-20020006443-A1 | Drug in a solubility-improved form with a concentration-enhancing polymer such as hydroxypropyl methyl cellulose acetate succinate; combination improves bioavailability relative to a control of just solubility improved form | BEND RESEARCH, INC. | 2002-01-17 | — | — | US | claimed |
| US-20010053778-A1 | Pharmaceutical compositions of glycogen phosphorylase inhibitors | BEND RESEARCH, INC. | 2001-12-20 | — | — | US | claimed |
| US-20010053791-A1 | Glycogen phosphorylase inhibitor | BEND RESEARCH, INC. | 2001-12-20 | — | — | US | claimed |
| WO-2001068055-A1 | PHARMACEUTICAL COMPOSITIONS OF GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2001-09-20 | — | — | WO | claimed |
| WO-2001068092-A2 | GLYCOGEN PHOSPHORYLASE INHIBITOR | PFIZER PRODUCTS INC. (US) | 2001-09-20 | — | — | WO | claimed |
| WO-2001047495-A1 | PHARMACEUTICAL COMPOSITIONS PROVIDING ENHANCED DRUG CONCENTRATIONS | PFIZER PRODUCTS INC. (US) | 2001-07-05 | — | — | WO | claimed |
| WO-2001047492-A1 | IMPROVED PHARMACEUTICAL COMPOSITIONS FOR POORLY SOLUBLE DRUGS | F H FAULDING & CO LIMITED (AU) | 2001-07-05 | — | — | WO | claimed |
| EP-1027886-A2 | Pharmaceutical solid dispersions | Pfizer Products Inc. (US) | 2000-08-16 | — | — | EP | claimed |
| EP-1027887-A2 | Matrix controlled release device | Pfizer Products Inc. (US) | 2000-08-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207264-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING INHIBITORS OF THE ANDROGEN RECEPTOR AND USES THEREOF | AR, NR5A1, SHBG | CA12 1411/4885CA1 2301/4885CA2 840/4885 |
| US-20010053791-A1 | Glycogen phosphorylase inhibitor | PYGL, PYGM, GYS2 | CA12 2425/4885CA1 2434/4885CA2 1869/4885 |
| US-20010053778-A1 | Pharmaceutical compositions of glycogen phosphorylase inhibitors | PYGL, PYGM, GYS2 | CA12 2636/4885CA1 3278/4885CA2 1162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.